TY - JOUR
T1 - Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort
AU - Kim, Min
AU - Snowden, Stuart
AU - Suvitaival, Tommi
AU - Ali, Ashfaq
AU - Merkler, David J
AU - Ahmad, Tahmina
AU - Westwood, Sarah
AU - Baird, Alison
AU - Proitsi, Petroula
AU - Nevado-Holgado, Alejo
AU - Hye, Abdul
AU - Bos, Isabelle
AU - Vos, Stephanie
AU - Vandenberghe, Rik
AU - Teunissen, Charlotte
AU - Ten Kate, Mara
AU - Scheltens, Philip
AU - Gabel, Silvy
AU - Meersmans, Karen
AU - Blin, Olivier
AU - Richardson, Jill
AU - De Roeck, Ellen
AU - Sleegers, Kristel
AU - Bordet, Régis
AU - Rami, Lorena
AU - Kettunen, Petronella
AU - Tsolaki, Magda
AU - Verhey, Frans
AU - Sala, Isabel
AU - Lléo, Alberto
AU - Peyratout, Gwendoline
AU - Tainta, Mikel
AU - Johannsen, Peter
AU - Freund-Levi, Yvonne
AU - Frölich, Lutz
AU - Dobricic, Valerija
AU - Engelborghs, Sebastiaan
AU - Frisoni, Giovanni B
AU - Molinuevo, José L
AU - Wallin, Anders
AU - Popp, Julius
AU - Martinez-Lage, Pablo
AU - Bertram, Lars
AU - Barkhof, Frederik
AU - Ashton, Nicholas
AU - Blennow, Kaj
AU - Zetterberg, Henrik
AU - Streffer, Johannes
AU - Visser, Pieter J
AU - Lovestone, Simon
AU - Legido-Quigley, Cristina
PY - 2019/6
Y1 - 2019/6
N2 - INTRODUCTION: A critical and as-yet unmet need in Alzheimer's disease (AD) is the discovery of peripheral small molecule biomarkers. Given that brain pathology precedes clinical symptom onset, we set out to test whether metabolites in blood associated with pathology as indexed by cerebrospinal fluid (CSF) AD biomarkers.METHODS: This study analyzed 593 plasma samples selected from the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery study, of individuals who were cognitively healthy (n = 242), had mild cognitive impairment (n = 236), or had AD-type dementia (n = 115). Logistic regressions were carried out between plasma metabolites (n = 883) and CSF markers, magnetic resonance imaging, cognition, and clinical diagnosis.RESULTS: Eight metabolites were associated with amyloid β and one with t-tau in CSF, these were primary fatty acid amides (PFAMs), lipokines, and amino acids. From these, PFAMs, glutamate, and aspartate also associated with hippocampal volume and memory.DISCUSSION: PFAMs have been found increased and associated with amyloid β burden in CSF and clinical measures.
AB - INTRODUCTION: A critical and as-yet unmet need in Alzheimer's disease (AD) is the discovery of peripheral small molecule biomarkers. Given that brain pathology precedes clinical symptom onset, we set out to test whether metabolites in blood associated with pathology as indexed by cerebrospinal fluid (CSF) AD biomarkers.METHODS: This study analyzed 593 plasma samples selected from the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery study, of individuals who were cognitively healthy (n = 242), had mild cognitive impairment (n = 236), or had AD-type dementia (n = 115). Logistic regressions were carried out between plasma metabolites (n = 883) and CSF markers, magnetic resonance imaging, cognition, and clinical diagnosis.RESULTS: Eight metabolites were associated with amyloid β and one with t-tau in CSF, these were primary fatty acid amides (PFAMs), lipokines, and amino acids. From these, PFAMs, glutamate, and aspartate also associated with hippocampal volume and memory.DISCUSSION: PFAMs have been found increased and associated with amyloid β burden in CSF and clinical measures.
KW - Alzheimer's disease
KW - Amyloid
KW - Biomarkers
KW - Brain volume measurements
KW - CSF
KW - Cognitive function measurements
KW - Dementia
KW - EMIF-AD
KW - Metabolomics
KW - Tau
UR - http://www.scopus.com/inward/record.url?scp=85066602218&partnerID=8YFLogxK
U2 - 10.1016/j.jalz.2019.03.004
DO - 10.1016/j.jalz.2019.03.004
M3 - Article
C2 - 31078433
SN - 1552-5260
VL - 15
SP - 817
EP - 827
JO - Alzheimer's & Dementia
JF - Alzheimer's & Dementia
IS - 6
ER -